BTW, as discussed before, Matinas is nothing for Amarin longs to worry about. No one who claims otherwise should be taken seriously.
A quick glance at the Matinas website shows the crown jewel of their scientific achievement is a poster from about 2015 about a tiny (less than 30 days, less than 50 subjects), unpublished, un-blinded trial of Mat9001 (a blend of omega-3s including EPA and DPA) compared to Vascepa. They compare the increases of plasma EPA, and, as Adam Feuerstein noted in a Stat article a few months ago, their results for Vascepa were significantly different (worse) from confirmed data from much larger, published, FDA-reviewed Vascepa trials. Matinas' patent portfolio is also unimpressive. They discontinued work on Mat9001 for years until dusting it off after RI.
It seems quite clear Matinas is trying to coat tail RI and license their tech or just boost their share price. Any FDA approval for CVD would require a major outcomes trial (9 figures cost and probably at least 8 years before approval in the unlikely event anyone undertakes it and it succeeds). V goes generic in Aug 2029. The market doesn't seem to be falling for it much, share price is quite low after a brief modest bump up following RI, pretty much evaporated now. They recently hired some scientific advisors with impressive credentials, but that doesn't change the facts and their dim prospects.
